MRI of transgenic mouse lungs with EGFR-driven lung adenocarcinoma, before and after treatment with CO-1686

A first-of-its-kind drug is showing early promise in attacking certain lung cancers that are hard to treat because they build up resistance to conventional chemotherapy.

The drug, CO-1686, performed well in a preclinical study involving xenograft and transgenic mice, as reported in the journal Cancer Discovery. It is now being evaluated for safety and efficacy in Phase I and II clinical trials.

Ligia Pinto

Scientists have identified 11 inflammation markers in the bloodstream that are associated with an increased risk of lung cancer.

Previous studies of inflammation markers have been on a smaller scale or involved fewer markers. The current study, published in the Journal of the National Cancer Institute, examined 68 markers associated with various aspects of immunity and inflammation.

Pages